The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
Open accessAbstract
Multiple steps are involved in the metastasis of cancer cells from primary sites to distant organs. These steps should be considered in the design of pharmacologic approaches to prevent or inhibit the metastatic process. In the present study, we have compared the effects of inhibiting several steps involved in the bone metastatic process individually with inhibition of both together. The steps we chose were matrix metalloproteinase (MMP) secretion, likely involved in tumor cell invasion, and osteoclastic bone resorption, the final step in the process. We used an experimental model in which inoculation of human estrogen-independent breast cancer MDA-231 cells into the left cardiac ventricle of female nude mice causes osteolytic lesions in bone. To inhibit cancer invasiveness, the tissue inhibitor of the MMP-2 (TIMP-2), which is a natural inhibitor of MMPs, was overexpressed in MDA-231 cells. To inhibit bone resorption, a potent bisphosphonate, ibandronate (4 microg/mouse) was daily administered subcutaneously. Nude mice received either; (a) nontransfected MDA-231 cells; (b) nontransfected MDA231 cells and ibandronate; (c) TIMP-2-transfected MDA-231 cells; or (d) TIMP-2-transfected MDA-231 cells and ibandronate. In mice from group a, radiographs revealed multiple osteolytic lesions. However, in mice from group b or group c, osteolytic lesions were markedly decreased. Of particular note, in animals from group d receiving both ibandronate and TIMP-2-transfected MDA-231 cells, there were no radiologically detectable osteolytic lesions. Survival rate was increased in mice of groups c and d. There was no difference in local enlargement in the mammary fat pad between nontransfected and TIMP-2-transfected MDA-231 cells. These results suggest that inhibition of both MMPs and osteoclastic bone resorption are more efficacious treatment for prevention of osteolytic lesions than either alone, and suggest that when therapies are designed based on the uniqueness of the bone microenvironment and combined with several common steps in the metastatic process, osteolytic bone metastases can be more efficiently and selectively inhibited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tjäderhane, L., Buzalaf, M. A. R., Carrilho, M., & Chaussain, C. (2015) · Caries Research · doi:10.1159/000363582 · Cited by 2,306
Arteaga, C. L., Hurd, S. D., Winnier, A. R., Johnson, M. D., Fendly, B. M., & Forbes, J. T. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116871 · Cited by 359
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Mühlbauer, R. C., Bauss, F., Schenk, R., Janner, M., Bosies, E., Strein, K., & Fleisch, H. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650060915 · Cited by 239 · cited 1×
“We then examined the effects of a combination of TIMP-2 overexpression and ibandronate, another potent bisphosphonate (14), compared with those of each single treatment.”
ResultSelf-citationBlavier, L., & Delaissé, J. M. (1995) · Journal of Cell Science · doi:10.1242/jcs.108.12.3649 · Cited by 221
Cited by
Bisphosphonates: mechanisms of action.
Rodan, G. A., & Fleisch, H. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118722 · Cited by 921
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I. J., Solomayer, E.-F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
Matrix metalloproteinases: multifunctional contributors to tumor progression
McCawley, L. J., & Matrisian, L. M. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(00)01686-5 · Cited by 643
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis
Duffy, M. J., Maguire, T. M., Hill, A., McDermott, E., & O'Higgins, N. (2000) · Breast Cancer Research · doi:10.1186/bcr65 · Cited by 628
Yoneda, T., Williams, P. J., Hiraga, T., Niewolna, M., & Nishimura, R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.8.1486 · Cited by 473
Self-citationMatrix Metalloproteinase-2 Contributes to Cancer Cell Migration on Collagen
Xu, X., Wang, Y., Chen, Z., Sternlicht, M. D., Hidalgo, M., & Steffensen, B. (2005) · Cancer Research · doi:10.1158/0008-5472.130.65.1 · Cited by 413
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Body, J. J., Bartl, R., Burckhardt, P., Delmas, P. D., Diel, I. J., Fleisch, H., Kanis, J. A., Kyle, R. A., Mundy, G. R., Paterson, A. H., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3890 · Cited by 359
Self-citationAntitumor effects of bisphosphonates
Green, J. R. (2003) · Cancer · doi:10.1002/cncr.11128 · Cited by 311
Crosstalk between cancer cells and bone microenvironment in bone metastasis
Yoneda, T., & Hiraga, T. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.070 · Cited by 308
Self-citationLu, X., Wang, Q., Hu, G., Van Poznak, C., Fleisher, M., Reiss, M., Massagué, J., & Kang, Y. (2009) · Genes & Development · doi:10.1101/gad.1824809 · Cited by 304
Bisphosphonates Induce Breast Cancer Cell Death In Vitro
Fromigue, O., Lagneaux, L., & Body, J.-J. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.11.2211 · Cited by 276
Requirement for Arf6 in breast cancer invasive activities
Hashimoto, S., Onodera, Y., Hashimoto, A., Tanaka, M., Hamaguchi, M., Yamada, A., & Sabe, H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401753101 · Cited by 270
Mechanisms of osteolytic bone metastases in breast carcinoma
K�k�nen, S.-M., & Mundy, G. R. (2003) · Cancer · doi:10.1002/cncr.11132 · Cited by 269
Self-citationHicks, D. G., Short, S. M., Prescott, N. L., Tarr, S. M., Coleman, K. A., Yoder, B. J., Crowe, J. P., Choueiri, T. K., Dawson, A. E., Budd, G. T., et al. (2006) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213306.05811.b9 · Cited by 262
Clines, G. A., & Guise, T. A. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.00543 · Cited by 253
Proteinases in bone resorption: obvious and less obvious roles
Delaissé, J.-M., Engsig, M. T., Everts, V., del Carmen Ovejero, M., Ferreras, M., Lund, L., Vu, T. H., Werb, Z., Winding, B., Lochter, A., et al. (2000) · Clinica Chimica Acta · doi:10.1016/s0009-8981(99)00230-2 · Cited by 227
Price, J. T., Quinn, J. M. W., Sims, N. A., Vieusseux, J., Waldeck, K., Docherty, S. E., Myers, D., Nakamura, A., Waltham, M. C., Gillespie, M. T., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4458 · Cited by 142
RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
Kitazawa, S., & Kitazawa, R. (2002) · The Journal of Pathology · doi:10.1002/path.1199 · Cited by 141
“tumour cell lines into nude mice has been established to observe haematogenous cancer metastases to long bones [2,18,19].”
BackgroundMancino, A. T., Klimberg, V. S., Yamamoto, M., Manolagas, S. C., & Abe, E. (2001) · Journal of Surgical Research · doi:10.1006/jsre.2001.6204 · Cited by 138
Metadata
- Authors
- Yoneda, T., Sasaki, A., Dunstan, C., Williams, P. J., Bauss, F., De Clerck, Y. A., & Mundy, G. R.
- Venue
- Journal of Clinical Investigation
- Published
- 1997-05-15
- Volume
- 99
- Issue
- 10
- Pages
- 2509-2517
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2059387208
- Cited by
- 247
- References
- 4
- FWCI
- 7.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.